Zimmer Biomet Holdings Inc (ZBH)
Official siteHEALTHCARE • MEDICAL DEVICES • NYSE
Market Cap: $19.53B
Last updated: Nov 17, 2026 at 11:06 AM ET
Zimmer Biomet Holdings Inc (ZBH) Financials: Revenue, Profit and Cash Flow
Zimmer Biomet Holdings reported revenue of $8.23B for the fiscal year ended Dec 31, 2025, up 7.2% from the year before. That year, net income was $705.10M with a net margin of 8.6%, operating cash flow was $1.70B and free cash flow was $1.47B. The quarter ended Sep 30, 2026 had revenue of $2.06B and net income of $191.60M.
Revenue and Margins
The operating margin was 13.3% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $7.62B, a compound annual rate of 0.9%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $8.23B | +7.2% | 69.7% | 13.3% | 8.6% |
| Dec 2024 | $7.68B | +3.8% | 71.5% | 16.7% | 11.8% |
| Dec 2023 | $7.39B | +6.5% | 71.8% | 17.3% | 13.8% |
| Dec 2022 | $6.94B | +1.6% | 70.9% | 10.0% | 3.3% |
| Dec 2021 | $6.83B | +11.4% | 71.3% | 12.6% | 5.9% |
| Dec 2020 | $6.13B | -23.2% | 70.2% | 1.4% | -2.2% |
| Dec 2019 | $7.98B | +0.6% | 71.8% | 14.3% | 14.2% |
| Dec 2018 | $7.93B | +1.7% | 71.4% | 0.4% | -4.8% |
| Dec 2017 | $7.80B | +2.5% | 72.7% | 10.2% | 23.2% |
| Dec 2016 | $7.62B | N/A | 68.7% | 10.8% | 4.0% |
Income Statement
In the fiscal year ended Dec 2025, net income fell 22.0% from the year before. In the quarter ended Sep 2026, net income fell 17.0% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8.23B | $7.68B | $7.39B | $6.94B | $6.83B | $6.13B | $7.98B | $7.93B | $7.80B | $7.62B |
| Cost of revenue | $2.49B | $2.19B | $2.08B | $2.02B | $1.96B | $1.82B | $2.25B | $2.27B | $2.13B | $2.38B |
| Gross profit | $5.74B | $5.49B | $5.31B | $4.92B | $4.87B | $4.30B | $5.73B | $5.66B | $5.67B | $5.23B |
| Research and development | $458.50M | $437.40M | $458.70M | $406.00M | $435.80M | $322.80M | $449.30M | $391.70M | $369.90M | $365.60M |
| Operating income | $1.10B | $1.29B | $1.28B | $696.30M | $860.30M | $83.10M | $1.14B | $33.80M | $799.30M | $821.10M |
| Net income | $705.10M | $903.80M | $1.02B | $231.40M | $401.60M | -$137.40M | $1.13B | -$379.30M | $1.81B | $304.60M |
| EBITDA | $2.22B | $2.25B | $2.22B | $1.49B | $1.81B | $1.01B | $2.14B | $1.06B | $1.85B | $1.79B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.06B | $2.18B | $2.09B | $2.24B | $2.00B | $2.08B | $1.91B | $2.02B | $1.82B | $1.94B | $1.89B | $1.94B |
| Gross profit | $1.47B | $1.54B | $1.51B | $1.45B | $1.44B | $1.49B | $1.36B | $1.44B | $1.29B | $1.39B | $1.38B | $1.40B |
| Operating income | $307.60M | $326.10M | $373.20M | $154.50M | $351.30M | $300.00M | $292.30M | $389.00M | $279.50M | $351.30M | $265.90M | $354.20M |
| Net income | $191.60M | $198.30M | $238.10M | $139.40M | $230.90M | $152.80M | $182.00M | $239.50M | $249.10M | $242.80M | $172.40M | $418.90M |
Balance Sheet
As of Dec 2025, total debt of $7.52B exceeded cash and equivalents by $6.93B.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $23.09B | $21.37B | $21.50B | $21.07B | $23.46B | $24.42B | $24.64B | $24.13B | $26.01B | $26.68B |
| Current assets | $5.12B | $4.67B | $4.61B | $4.43B | $4.88B | $5.08B | $4.72B | $4.43B | $4.56B | $4.66B |
| Cash and equivalents | $591.90M | $525.50M | $415.80M | $375.70M | $378.10M | $802.10M | $617.90M | $542.80M | $524.40M | $634.10M |
| Total liabilities | $10.39B | $8.89B | $9.01B | $9.04B | $10.79B | $12.22B | $12.25B | $12.85B | $14.28B | $17.01B |
| Short-term debt | $587.10M | $863.00M | $900.00M | $544.30M | $1.61B | $500.00M | $1.50B | $525.00M | $1.23B | $575.60M |
| Long-term debt | $6.93B | $5.34B | $4.87B | $5.15B | $5.46B | $7.63B | $6.72B | $8.41B | $8.92B | $10.67B |
| Shareholder equity | $12.70B | $12.47B | $12.48B | $12.02B | $12.66B | $12.19B | $12.39B | $11.27B | $11.74B | $9.67B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $23.54B | $22.80B | $22.72B | $23.09B | $23.49B | $22.87B | $22.18B | $21.37B | $21.72B | $21.52B | $21.45B | $21.50B |
| Total liabilities | $10.81B | $10.17B | $10.04B | $10.39B | $10.72B | $10.33B | $9.78B | $8.89B | $9.34B | $8.77B | $8.85B | $9.01B |
| Cash and equivalents | $399.90M | $410.00M | $424.20M | $591.90M | $1.29B | $556.90M | $1.38B | $525.50M | $569.00M | $420.10M | $393.00M | $415.80M |
| Shareholder equity | $12.72B | $12.62B | $12.67B | $12.70B | $12.76B | $12.53B | $12.40B | $12.47B | $12.37B | $12.74B | $12.60B | $12.48B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 86.5% of operating cash flow. Dividends and share repurchases together came to 46.1% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.70B | $1.50B | $1.58B | $1.36B | $1.40B | $1.08B | $1.59B | $1.75B | $1.58B | $1.63B |
| Capital expenditures | $224.50M | $203.80M | $291.10M | $187.90M | $143.60M | $111.90M | $207.10M | $162.70M | $156.00M | $184.70M |
| Free cash flow | $1.47B | $1.30B | $1.29B | $1.17B | $1.26B | $963.70M | $1.38B | $1.58B | $1.43B | $1.45B |
| Dividends paid | $190.30M | $196.00M | $200.90M | $201.20M | $345.10M | $198.50M | $196.70M | $195.20M | $193.60M | $188.40M |
| Share repurchases | $487.00M | $868.00M | $692.20M | $126.40M | $0 | $0 | N/A | N/A | N/A | $415.50M |
| Investing cash flow | -$1.98B | -$888.10M | -$778.90M | -$522.00M | -$443.30M | -$564.30M | -$729.30M | -$416.60M | -$510.80M | -$1.69B |
| Financing cash flow | $326.00M | -$484.50M | -$763.50M | -$775.70M | -$1.31B | -$420.20M | -$779.90M | -$1.30B | -$1.21B | -$743.20M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $560.00M | $447.80M | $359.40M | $517.40M | $418.70M | $378.20M | $382.80M | $506.30M | $395.70M | $369.40M | $228.00M | $588.40M |
| Capital expenditures | $75.80M | $54.20M | $36.30M | $74.80M | $55.00M | $50.10M | $44.60M | $51.50M | $44.50M | $52.70M | $55.10M | $62.80M |
| Free cash flow | $484.20M | $393.60M | $323.10M | $442.60M | $363.70M | $328.10M | $338.20M | $454.80M | $351.20M | $316.70M | $172.90M | $525.60M |
Frequently Asked Questions About ZBH
What is Zimmer Biomet Holdings' annual revenue?
Zimmer Biomet Holdings reported revenue of $8.23B for the fiscal year ended Dec 31, 2025.
How fast is Zimmer Biomet Holdings' revenue growing?
Revenue was up 7.2% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 5.9%.
Is Zimmer Biomet Holdings profitable?
Yes. Zimmer Biomet Holdings reported net income of $705.10M for the fiscal year ended Dec 31, 2025, with a net margin of 8.6%.
How much free cash flow does ZBH generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $1.70B minus capital expenditures of $224.50M produced free cash flow of $1.47B.
How much debt does Zimmer Biomet Holdings have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $6.93B, short-term debt of $587.10M and cash and equivalents of $591.90M.
ZBH pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts